Background: Antipsychotic switching is routine in clinical practice, although it remains unclear which is the preferable switching method: immediate discontinuation of the current antipsychotic or a gradual tapering approach. The first strategy has been implicated in rebound/withdrawal symptoms and emergence/exacerbation of symptoms, whereas the gradual approach is thought to pose a risk of additive or synergistic side effects if employed in the context of a crossover approach. Methods: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched. Randomized controlled trials examining immediate vs gradual antipsychotic discontinuation in antipsychotic switching in patients with schizophrenia and/ or schizoaffective disorder were selected. Data on clinical outcomes, including study discontinuation, psychopathology, extrapyramidal symptoms, and treatment-emergent adverse events, were extracted. Results: A total of 9 studies involving 1416 patients that met eligibility criteria were included in the meta-analysis. No significant differences in any clinical outcomes were found between the 2 approaches (all Ps > .05). Sensitivity analyses revealed that the findings remained unchanged in the studies where switching to aripiprazole was performed or where immediate initiation of the next antipsychotic was adopted, while some significant differences were observed in switching to olanzapine or ziprasidone. Conclusions: These findings indicate that either immediate or gradual discontinuation of the current antipsychotic medication represents a viable treatment option. Clinicians are advised to choose an antipsychotic switching strategy according to individual patient needs. This said, immediate discontinuation may be advantageous both for simplicity and because a stalled cross-titration process in antipsychotic switching could end up in antipsychotic polypharmacy.
Introduction
Switching to a different antipsychotic agent frequently occurs in clinical practice during the treatment of schizophrenia, most often related to suboptimal efficacy and/ or poor tolerability of the current agent. [1] [2] [3] The process of antipsychotic switching provides the opportunity for multiple strategies [4] [5] [6] [7] [8] that arise from the fundamental options available for each drug (ie, immediate vs gradual discontinuation of the current antipsychotic, as well as full dose vs incremental titration of the new antipsychotic). Variations can also include a gap between discontinuing the first and initiating the next antipsychotic. 9 As summarized in supplementary table 1, immediate antipsychotic discontinuation has been associated with the following risks: (1) dopamine supersensitivity syndromes (eg, supersensitivity psychosis and withdrawal dyskinesia); (2) rebound syndromes related to cholinergic, histaminergic, and serotonergic activity; and (3) emergence/exacerbation of symptoms. 4, 5, 7, 8, 10, 11 On the other hand, the gradual discontinuation has been linked with an increased risk of side effects that may be additive or synergistic when used in the context of a crossover approach. 4, 5, 7, 8, 11 It has been reported that clinicians are more likely to perform abrupt rather than cross-titration switching, [12] [13] [14] [15] while previous reviews of antipsychotic switching strategies recommend gradual antipsychotic discontinuation as a safer method in general 7, 8, 10, 11, 16 ; such endorsement is based on empirical evidence but not on actual data from clinical trials.
There have been several randomized controlled trials (RCTs) examining the 2 approaches. 9, [17] [18] [19] [20] [21] [22] [23] [24] In fact, a meta-analysis in 2004 by our group reported no differences in either efficacy or safety 25 although only 4 RCTs met criteria for inclusion at that time. 9, [17] [18] [19] However, a further 5 RCTs comparing these approaches have since been reported. [20] [21] [22] [23] [24] In light of how common antipsychotic switching occurs, this question remains no less relevant. In order to update information on this clinically important topic, we conducted a systematic review and meta-analysis of RCTs examining immediate vs gradual antipsychotic discontinuation in patients with schizophrenia undergoing a switch.
Methods

Literature Search and Study Selection
Two authors (H.T. and N.K.) independently conducted a systematic literature search in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) Statement. 26 MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched using the following keywords: (schizophr* OR schizoaff*) AND antipsychotic* AND switch* AND (strateg* OR tactic* OR techni* OR procedure*), with a limitation of English language (last search: August 30, 2016) . Studies that met the following eligibility criteria were selected: (1) RCTs; (2) studies including patients with schizophrenia and/or schizoaffective disorder; and (3) studies including both immediate and gradual antipsychotic discontinuation arms in antipsychotic switching. Risk of bias for each included study was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions (available at http://handbook.cochrane.org).
Data Extraction
Two authors (H.T. and N.K.) independently extracted the following clinical outcome data in both immediate and gradual antipsychotic discontinuation groups from the selected studies: (1) the number of patients who discontinued the study due to all causes, lack of efficacy, and adverse events; (2) mean ± SD changes from baseline to endpoint in the Positive and Negative Syndrome Scale (PANSS) 27 or the Brief Psychiatric Rating Scale (BPRS) 28 total and positive symptom, the PANSS negative subscale, and the Clinical Global Impression-Severity scale (CGI-S) 29 scores as psychopathology measures, and the Simpson-Angus Scale (SAS) 30 total, the Barnes Akathisia Rating Scale (BARS) 31 total or global, and the Abnormal Involuntary Movement Scale (AIMS) 29 total or Item 8 scores as extrapyramidal symptom (EPS) measures; and (3) the number of patients who experienced treatmentemergent adverse events (TEAEs) that were reported in ≥3 out of the identified 9 studies (these included akathisia, anxiety, diarrhea, headache, insomnia, nausea, and somnolence). If reports on the studies did not provide sufficient data, we contacted the corresponding authors and/or funding pharmaceutical company, accessed the ClinicalTrails.gov website, and/or applied to data-sharing organizations to which pharmaceutical companies sometimes belong in an attempt to obtain additional information.
There are 2 points that should be noted in the data extraction. First, since Lee et al 17 did not clearly report the number of patients who discontinued the study due to inefficacy, we used 0 for both groups, estimated by subtracting the total number of patients who discontinued the study due to specific causes from those discontinuing due to all causes in each group. Second, Kinon et al 9 did not report somnolence but rather "drowsiness," which we treated as synonomous. In addition, various descriptors of insomnia were reported including "shortened sleep," "difficulty falling asleep," "interrupted sleep," and "early waking" 9 ; we chose to use "shortened sleep" for insomnia but also conducted sensitivity analyses using each of the descriptors.
Data Analysis
Meta-analyses were performed using Review Manager (RevMan) version 5.3. Outcome data were combined and compared between immediate and gradual antipsychotic discontinuation groups. For dichotomous and continuous outcomes, pooled estimates of risk ratios (RRs) and standardized mean differences (SMDs) were calculated with 2-sided 95% confidence intervals (CIs) using a random-effects model, respectively.
Because we were able to obtain from Pfizer the individual data on all 3 studies included in a pooled analysis, 19 we treated this pooled analytic study as 3 separate studies (ie, Weiden 2003a, Weiden 2003b, and Weiden 2003c); in addition, to evaluate the impact of treating one pooled study as 3 separate studies, we conducted sensitivity analyses using pooled results. If any study included another switching strategy, we disregarded these group(s) as we were focused on comparing the immediate and gradual antipsychotic discontinuation strategies (supplementary  table 2 and compared arm (1) with arm (3) in one study, and arm (2) with arm (4) in the other study to match the antipsychotic initiation strategies (supplementary table 2 ); in addition, to evaluate the impact of treating one study as 2 separate studies, we conducted sensitivity analyses only using either one (ie, Kinon 2000a or Kinon 2000b). As a consequence, a total of 12 comparisons of immediate and gradual antipsychotic discontinuation were yielded.
As sensitivity analyses, we separately analyzed the following 5 sets of studies: (1) blinding raters (N = 4); (2) adopting an immediate antipsychotic initiation strategy (8 comparisons); (3) switching to olanzapine (N = 2); (4) switching to ziprasidone (N = 2); and (5) switching to aripiprazole (N = 2).
All effect sizes with a P < .05 were considered significant. Study heterogeneities were quantified using I 2 statistic with I 2 s ≥ 50% indicating significant heterogeneity.
Results
Included Studies
A total of 9 studies 9,17-24 involving 1416 patients (n = 714 and n = 702 for the immediate and gradual antipsychotic discontinuation, respectively) that met eligibility criteria were identified and included in the meta-analysis (supplementary figure 1). The characteristics of these studies are summarized in table 1. All studies represented parallelgroup RCTs with a relatively short duration, ranging from 3 to 12 weeks, and were published in 2000 or later. Only 1 study was conducted in a double-blind fashion, 3 were performed with raters blinded, and the remaining 5 were open-label studies. In the majority of studies, risperidone, olanzapine, or haloperidol were prescribed as the current antipsychotic prior to randomization; risperidone (N = 1), olanzapine (N = 2), ziprasidone (N = 2), aripiprazole (N = 2), iloperidone (N = 1), or clozapine (N = 1) were introduced as the new antipsychotic. In terms of gradual antipsychotic discontinuation procedures, the current antipsychotic were discontinued in 1, 2, 3, and 4 weeks in 3, 4, 1, and 1 report(s), respectively. In terms of initiation strategies of the new antipsychotic, 8 out of 12 comparisons used immediate initiation, while 4 used gradual or wait-and-gradual initiation (table 1 and  supplementary table 2) .
The results of risk of bias assessment are displayed in supplementary figure 2.
Study Discontinuation
There was no significant difference in the number of patients who discontinued the study due to all causes (RR = 1.10, 95% CI = 0.93-1.30), inefficacy (RR = 1.14, 95% CI = 0.62-2.09), or intolerability (RR = 1.08, 95% CI = 0.70-1.66) between the immediate and gradual antipsychotic discontinuation groups (figure 1); no significant study heterogeneities were observed for all study discontinuation outcomes among the studies.
Psychopathology
No significant differences were found in any psychopathology outcomes including the PANSS/BPRS total (SMD = −0.03, 95% CI = −0.17 to 0.11) and positive symptom (SMD = −0.00, 95% CI = −0.14 to 0.14), PANSS negative subscale (SMD = −0.05, 95% CI = −0.19 to 0.10), and CGI-S scores (SMD = −0.02, 95% CI = −0.14 to 0.10) between the 2 groups (figure 2). All I 2 s were 0%, indicating no study heterogeneities.
Extrapyramidal Symptoms
There was no significant difference in scores for the SAS (SMD = 0.12, 95% CI = −0.11 to 0.35), BARS (SMD = 0.16, 95% CI = −0.33 to 0.65), or AIMS (SMD = 0.27, 95% CI = −0.03 to 0.56) between the 2 groups (figure 3). Although not statistically significant, the AIMS score tended in favor of gradual antipsychotic discontinuation (P = .07); however, both baseline and endpoint AIMS Item 8 (ie, global) scores were <1 (minimal) for all studies included in the meta-analysis. No significant heterogeneities were found in all EPS outcomes; however, there was a marginally significant study heterogeneity for the BARS (P = .06).
Treatment-Emergent Adverse Events
There were no significant differences in the number of patients who experienced any TEAEs (ie, akathisia, anxiety, diarrhea, headache, insomnia, nausea, and somnolence) between the immediate and gradual antipsychotic discontinuation groups ( figure 4) ; however, the former tended to have a less favorable outcome in terms of insomnia (P = .09). None of the study heterogeneities for any TEAEs was significant. Although all types of insomnia reported in Kinon et al 9 were separately used for insomnia in sensitivity analyses, none was significant (data not shown).
Sensitivity Analyses
No significant differences in any clinical outcomes were observed between the 2 groups in the following study data sets: blinding raters; adopting an immediate antipsychotic initiation strategy; and switching to aripiprazole (all Ps > .05) (data not shown). In addition, no significant differences were found in either data set using Kinon 2000a or Kinon 2000b, and the data set using pooled results of Weiden 2003a, Weiden 2003b, and Weiden 2003c. On the other hand, in switching to olanzapine there was a significant difference regarding insomnia (RR = 2.62, 95% CI = 1.30-5.29, P = .007) in favor of gradual discontinuation, while in switching to ziprasidone there were significant differences in the SAS scores (SMD = 0.33, 95% CI = 0.00-0.65, P = .05) and somnolence (RR = 0.25, 95% CI = 0.06-0.97, P = .05) in favor of gradual and immediate discontinuation, respectively. These findings are notably at odds with numerous reviews of antipsychotic switching strategies that recommend gradual discontinuation of the current antipsychotic to avoid rebound/withdrawal symptoms. 7, 8, 10, 11, 16 One possible explanation relates to the fact that the half-life for antipsychotic-related dopamine D 2 receptor occupancy centrally, as assessed with positron emission tomography (PET), is considerably longer than plasma half-life. 32, 33 This, in turn, may act as a buffer in the face of abrupt antipsychotic discontinuation. It should be noted, though, that marginally significant differences in tardive dyskinesia and insomnia were observed, at face value favoring gradual antipsychotic discontinuation although the severity of tardive dyskinesia at both baseline and endpoint was minimal (ie, <1 in the AIMS global score) for all studies included in the meta-analysis. However, this finding could as well reflect different pharmacological properties beyond dopamine, as well as dose equivalents, between the current and new antipsychotic being initiated. 7, 8, 10, 11, 16 For example, insomnia may be caused by a rapid switch to an antipsychotic agent with less potential to antagonize histamine H 1 receptors. 8, 10, 11, 16 Notably, no differences in psychopathology were found between immediate and gradual antipsychotic discontinuation in switching, which is of interest given that literature suggests dopamine supersensitivity psychosis can occur if patients stop antipsychotics abruptly. 34 Finally, a switch that entails moving to a more effective or tolerable antipsychotic may mitigate risk of clinical worsening or adverse effects regardless of switching strategy.
Immediate vs Gradual Antipsychotic Discontinuation
In this meta-analysis, we focused on immediate and gradual discontinuation of the current antipsychotic. Nonetheless, 1 RCT 35 and 4 arms of the included RCTs [19] [20] [21] [22] comparing gradual vs wait-and-gradual discontinuation (supplementary table 2 ) failed to demonstrate significant differences in the majority of clinical outcomes between the 2 strategies, which further supports the notion that discontinuation strategies of the current antipsychotic do not have any substantial clinical impact. As discussed, how the new antipsychotic is introduced is also important. Strategies can vary as a function of dose and titration strategies, and on occasion strategies may also employ a gap between discontinuation of the first 
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antipsychotic and initiation of the next agent. Sensitivity analysis including 8 comparisons that used an immediate introduction approach of the next antipsychotic found no significant differences in any clinical outcomes between immediate and gradual discontinuation of the current antipsychotic. This left only 4 comparisons that used other types of introduction strategies, hampering any conclusions that can be drawn regarding how to introduce the new antipsychotic.
In addition, differences in dose equivalents as well as pharmacological properties must also be taken into consideration when performing an antipsychotic switch. For example, a switch to aripiprazole or, alternatively, a switch from quetiapine/clozapine calls into play issues not relevant to switches involving other antipsychotics, the former related to aripiprazole's partial dopamine agonist properties and low affinity vis-a-vis other receptors, while the latter must take into account their low D 2 receptor affinity. 8 Sensitivity analyses revealed that none of the clinical outcomes significantly differed between immediate and gradual antipsychotic discontinuation strategies in those studies switching to aripiprazole, while in switching to olanzapine or ziprasidone some significant differences were found, suggesting that clinicians need to take into account the pharmacological profiles of the next antipsychotic, in particular for antipsychotics that have a sedative effect such as olanzapine. However, each involves only 2 reports and further studies are clearly needed.
There are limitations to the present study that warrant comment. First, we were not able to obtain certain additional data, including the number of patients who discontinued in one of the largest studies of Kinon et al. 9 In addition, 1 RCT examining immediate vs wait-and-gradual discontinuation of the current antipsychotic with a switch to sertindole 36 was not included in the meta-analysis because no usable data were presented; this study reported no significant differences in the vast majority of clinical outcomes between the 2 strategies. Second, there were some variations in duration of gradual antipsychotic discontinuation strategies among the studies, as noted in the "Results" section. Third, only 1 study was conducted in a double-blind fashion, which may have influenced findings. Fourth, study durations were relatively short, although rebound/withdrawal symptoms are reported to usually occur within weeks following an antipsychotic switch. 4 Fifth, despite the frequency of antipsychotic switching in actual clinical practice, the number of studies investigating this issue remains limited, raising the possibility of type II error. Lastly, most of the studies were presumed to largely recruit patients with chronic schizophrenia, as reflected in the established mean age of approximately 35-45 years (illness duration was provided in only 3 studies), which may limit the generalizability of the present findings. Further long-term, double-blind RCTs in patients with schizophrenia at various stages of the illness are needed.
In conclusion, the current meta-analysis of 9 RCTs examining antipsychotic switching strategies demonstrated no significant differences in clinical outcomes between immediate and gradual antipsychotic discontinuation in schizophrenia, indicating that either immediate or gradual discontinuation of the current antipsychotic medication represents a viable treatment option. In clinical practice, gradual discontinuation is frequently observed because of the widely held notion that this method diminishes risk of symptom exacerbation and/ or side effects-this strategy is recommended as a safer method in previous reviews. However, evidence thus far does not necessarily support this notion. Clinicians are advised to choose an antipsychotic switching strategy according to individual patient needs. This said, immediate antipsychotic discontinuation may be advantageous both for simplicity and because a stalled cross-titration process in antipsychotic switching could end up in antipsychotic polypharmacy.
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